Opus Point Partners Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Opus Point Partners Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-20,595	Closed	-$176K	–	72
2017 Q1	$176K	Buy	+20,595	New	+$188K	0.13%	66
2015 Q4	–	Sell	-75,000	Closed	-$662K	–	66
2015 Q3	$662K	Hold	75,000	–	–	0.37%	40
2015 Q2	$883K	Hold	75,000	–	–	0.7%	38
2015 Q1	$1.08M	Buy	75,000 +4,600	+7%	+$70.4K	0.91%	31
2014 Q4	$1.2M	Buy	+70,400	New	+$1.02M	1.19%	29

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Opus Point Partners Management's STML Position: Q2 2017 in Review

Opus Point Partners Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2017, closing a stake of 20,595 shares — an estimated $176K sold.

Opus Point Partners Management first reported a position in STML in Q4 2014 and held it in 5 quarters. The position peaked at $1.2M in Q4 2014. 70 funds tracked by Wall St. Rank hold STML as of Q2 2017.

Opus Point Partners Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Opus Point Partners Management sold 20,595 Stemline Therapeutics, Inc. shares in Q2 2017, an estimated $176K.
Opus Point Partners Management first reported a position in Stemline Therapeutics, Inc. in Q4 2014 and held it in 5 quarters.
Opus Point Partners Management's Stemline Therapeutics, Inc. position peaked at $1.2M in Q4 2014.
70 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2017.

Based on Opus Point Partners Management's 13F filing for Q2 2017, filed 14 Aug 2017.